Baxter International Inc. (BAX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- RNA Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.52% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors
- Are Investors Undervaluing Baxter International (BAX) Right Now?
- Baxter Releases Inaugural Connected Hospital Report
- Global Remote Cardiac Monitoring Market Size, Share & Trends Analysis 2026-2036 Featuring Profiles of Medtronic, Abbott Labs, Boston Scientific, GE HealthCare Technologies, Philips, Baxter International (Hillrom) and Other Key Players
- Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
- 2 Volatile Stocks for Long-Term Investors and 1 Facing Challenges
- Is Baxter Stock Underperforming the Nasdaq?
- BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Baxter International Inc..
Full BAX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.